Over 2 years have passed since the start of the COVID-19 pandemic, which has claimed
millions of lives. Unlike the early days of the pandemic, when management decisions were …

The COVID-19 pandemic is one of the greatest threats to human health in the 21st century
with more than 257 million cases and over 5.17 million deaths reported worldwide (as of …

Background Early administration of convalescent plasma obtained from blood donors who
have recovered from coronavirus disease 2019 (Covid-19) may prevent disease …

Background Convalescent plasma and hyperimmune immunoglobulin may reduce mortality
in patients with viral respiratory diseases, and are currently being investigated in trials as …

Importance The evidence for benefit of convalescent plasma for critically ill patients with
COVID-19 is inconclusive. Objective To determine whether convalescent plasma would …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel virus that spread
worldwide from 2019 causing the Coronavirus disease 19 (COVID-19) pandemic. SARS …

Convalescent plasma (CP) recurs as a frontline treatment in epidemics because it is
available as soon as there are survivors. The COVID-19 pandemic represented the first …

Background Recently, the coronavirus (COVID-19) pandemic is a chief public health
disaster caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There …

The COVID-19 pandemic has presented a serious challenge to the hepatology community,
particularly healthcare professionals and patients. While the rapid development of safe and …

Background Convalescent plasma has been proposed as an early treatment to interrupt the
progression of early COVID-19 to severe disease, but there is little definitive evidence. We …